PTO/SB/26 (07-09)

Approved for use through 07/31/2012 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Linder the Paperwork Reduction Act of 1995, no persons are required to raspond to a collection of information unless it displays a valid OMB control number

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A "PRIOR" PATENT	22064-71990
In re Application of: Koppel et al.	
Application No.: 10/620,221	
Filed: July 15, 2003	
For: Neurotherapeutic Clavulanate Composition and Method	
The owner*, Revaax Pharmaceuticals LLC of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statulory term of any patent granted on the instant application which would extend beyond the expiration date of the full statulory term prior patent NoVPC702.56(608):81.6543-49, as term of said prior patent is deficed in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
In making the above disci aimer, the owner does not disclaim he terminal part of the term of any patient granted on the instant application that would advant of the expiration date of the full statutory term as defined in \$5.U.S. C. 154 and 17.9 of the prior patent. "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a count of competent jurisdiction; is found invalid by a count of competent jurisdiction; is statutorily disclaimed in whote or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a recamination certificate; is resissued; or is many manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on in formation and belief are belie ved to be true; and further that the ses statements were made with the knowledge that willful falses statements and the like so made are punis hable by fine or imprisonment, or both, under Se clino 101 of 111e 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an attorney or agent of record. Reg. No. 27321	
Mulany Manad Signature!	March 4, 2010 Date
Richard D. Conard	
Typed or printed name	
	317-231-7285
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of Information is required by 37 CFR 1.321. The information is required to obtain or retain, about if by the public which is so fise (each by the USETO to process) an application. Confidentiality is governed by 33 U.S.C. 120 at 27 CFR 1.31 at 1.1 th. This condection is submitted to the 12 channels to complete, to proceed the confidentiality is governed by 33 U.S.C. 120 at 27 CFR 1.31 at 1.1 th. This condection is submitted to the 12 channels to complete, to proceed the 120 CFR 1.31 at 1.31